The disclosure provides a method for treating an infection of SARS-CoV-2 infection in a subject, comprising administering to said subject a therapeutically effective amount of a peptide, which is a recombinant fragment human surfactant protein D. The disclosure also provides a pharmaceutical composition for treating an infection of SARS-CoV-2 infection comprising a therapeutically effective amount of the recombinant fragment human surfactant protein D and a pharmaceutically acceptable carrier.

The disclosure provides a method for treating an infection of SARS-CoV-2 infection in a subject, comprising administering to said subject a therapeutically effective amount of a peptide, which is a recombinant fragment human surfactant protein D. The disclosure also provides a pharmaceutical composition for treating an infection of SARS-CoV-2 infection comprising a therapeutically effective amount of the recombinant fragment human surfactant protein D and a pharmaceutically acceptable carrier.

Peptides suitable for preparation of lung surfactants are described. Examples include one that include a first fragment comprising the amino acid sequence of XWLXRALIKRIQAZI (SEQ ID NO: 1) or a first amino acid sequence having at least 90% sequence identity to SEQ ID NO: 1 and a second fragment comprising the amino acid sequence of RZLPQLVXRLVLRXS (SEQ ID NO: 2) or a second amino acid sequence having at least 90% sequence identity to SEQ ID NO: 2, wherein X is any amino acid but at least one amino acid at the X positions is not cysteine, or Z is any amino acid but at least one amino acid at the Z positions is not methionine. Surfactants that contain such peptides, and related compositions, methods of preparing and using the compositions are also described.

Peptides suitable for preparation of lung surfactants are described. Examples include one that include a first fragment comprising the amino acid sequence of XWLXRALIKRIQAZI (SEQ ID NO: 1) or a first amino acid sequence having at least 90% sequence identity to SEQ ID NO: 1 and a second fragment comprising the amino acid sequence of RZLPQLVXRLVLRXS (SEQ ID NO: 2) or a second amino acid sequence having at least 90% sequence identity to SEQ ID NO: 2, wherein X is any amino acid but at least one amino acid at the X positions is not cysteine, or Z is any amino acid but at least one amino acid at the Z positions is not methionine. Surfactants that contain such peptides, and related compositions, methods of preparing and using the compositions are also described.

Provided herein are compositions and methods for treating and preventing lung disease. In particular, provided herein are surfactant protein-A (SP-A) peptide analogies (e.g., SP-A peptidomimetics) and uses thereof in the treatment and prevention of lung disease (e.g., asthma or COPD).

Provided herein are compositions and methods for treating and preventing lung disease. In particular, provided herein are surfactant protein-A (SP-A) peptide analogies (e.g., SP-A peptidomimetics) and uses thereof in the treatment and prevention of lung disease (e.g., asthma or COPD).

The objective of the present invention is to provide an extinguishing agent which has excellent fire-extinguishing property and which exhibits high safety to the environment and human body. The fire extinguishing agent of the present invention is characterized in comprising a biosurfactant.

The objective of the present invention is to provide an extinguishing agent which has excellent fire-extinguishing property and which exhibits high safety to the environment and human body. The fire extinguishing agent of the present invention is characterized in comprising a biosurfactant.

Some embodiments of the methods and compositions provided herein relate to the preparation surfactant protein-D (SP-D). Some embodiments include the expression of human SP-D in certain cell lines, and the purification of human SP-D from such cell lines. Some embodiments include the preparation of certain oligomeric forms of human SP-D.

The present invention is directed respirable, dry powder particle formulations of lung surfactants that optionally comprise surfactant proteins and/or polypeptide and that are formulated for delivery to the pulmonary system via inhalation.